ruxolitinib cream vitiligo
Selected indexed studies
- Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. (N Engl J Med, 2022) [PMID:36260792]
- Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo. (Drugs, 2024) [PMID:38625661]
- Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. (Lancet, 2020) [PMID:32653055]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo. (2024) pubmed
- Topical ruxolitinib: A new treatment for vitiligo. (2023) pubmed
- Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. (2022) pubmed
- Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. (2020) pubmed
- Addition of Narrow-Band UVB Phototherapy to Ruxolitinib Cream in Patients With Vitiligo. (2022) pubmed
- Efficacy and Safety of Ruxolitinib Cream in Vitiligo by Patient Characteristic Subgroups: Descriptive Pooled Analysis From Two Phase 3 Studies. (2025) pubmed
- Effectiveness and safety of ruxolitinib cream in Chinese patients with nonsegmental vitiligo. (2025) pubmed
- Treatment of vitiligo with ruxolitinib cream in the TRuE-V1 and TRuE-V2 studies: a plain language summary of publication. (2025) pubmed
- Short-term (24 weeks) treatment efficacy and safety of ruxolitinib cream in participants with vitiligo: a systematic review and meta-analysis. (2024) pubmed
- Ruxolitinib cream (Opzelura) for nonsegmental vitiligo. (2022) pubmed